CytomX Therapeutics (NASDAQ:CTMX) Announces Quarterly Earnings Results

Key Points

• Q3 results missed expectations: CytomX reported a loss of $0.09 per share versus a $0.07 consensus loss, while revenue of $1.69 million came in well below the $10.38 million estimate.
• Varseta-M remains the central development focus: CytomX expects a January update on dose optimization and overall survival, and is targeting a potential registrational study in the first half of 2027, alongside expanded combination and cancer-type studies.
• Cash provides runway, but safety remains a risk: The company reported $348 million in cash, equivalents, and investments, sufficient to fund operations into the second half of 2028; however, grade 3 diarrhea and longer-term follow-up remain important clinical concerns.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02), FiscalAI reports. CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 38.46%. The business had revenue of $1.69 million during the quarter, compared to the consensus estimate of $10.38 million.

Here are the key takeaways from CytomX Therapeutics' conference call:

• Varseta-M is advancing toward a potential registrational study: CytomX expects a January update with dose-optimization data and the first overall-survival readout, and is targeting study initiation in the first half of 2027. The company says overall survival is expected to be the primary endpoint, though the study population and design have not yet been finalized.
• The company is expanding Varseta-M’s development: It plans to begin a bevacizumab/chemotherapy combination study by year-end, with second-line patients expected in the Phase II portion, and anticipates initial bevacizumab-combination data in the first half of 2027. New cohorts are also evaluating the drug in gastric, gastroesophageal, pancreatic, and biliary cancers.
• Gastrointestinal toxicity remains a key development risk. CytomX reported a 10% rate of grade 3 diarrhea in the first 20 dose-optimization patients after two months of follow-up, versus more than 30% in time-matched earlier cohorts; it aims to keep the rate at or below 20%, but longer follow-up is pending.
• CytomX reported a cash runway into the second half of 2028 on $348 million in cash, equivalents, and investments at quarter-end, including a $37 million payment from Regeneron for two additional collaboration targets. Management said the funds support its stated Varseta-M development priorities.
• Quarterly revenue fell while operating expenses rose: Q3 revenue was $1.7 million, down from $6 million a year earlier, primarily following the end of the Astellas collaboration; operating expenses increased to $25.2 million from $21.7 million.

CytomX Therapeutics Trading Up 2.3%

Shares of NASDAQ:CTMX traded up $0.05 on Friday, reaching $2.19. The company had a trading volume of 2,727,216 shares, compared to its average volume of 3,937,045. CytomX Therapeutics has a 52-week low of $2.11 and a 52-week high of $8.21. The firm's 50 day simple moving average is $2.71 and its 200-day simple moving average is $3.81. The firm has a market capitalization of $477.20 million, a PE ratio of -4.38 and a beta of 2.23.

Trending Headlines about CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $12 from $11 and maintained an Outperform rating, signaling continued optimism about CytomX’s prospects. Wedbush Raises Price Target
• Positive Sentiment: Varseta-M reported 20%–32% objective response rates and a seven-month median progression-free survival in late-line colorectal cancer. The program has FDA Fast Track designation, with pivotal-trial initiation planned for the first half of 2027. The company also had $367 million in cash and potential partnership milestones, although those milestones are contingent on future development and commercial progress. CytomX Stock Trading Near Cash Value
• Negative Sentiment: Third-quarter revenue was $1.69 million, well below analyst expectations of $10.38 million. CytomX reported a loss of $0.09 per share; one report characterized this as a $0.02-per-share miss against its consensus estimate. The revenue shortfall and continuing losses may weigh on sentiment. CytomX Q3 Results
• Negative Sentiment: The clinical-program outlook carries execution risk, and the cited analysis notes prior dilution and terminated legacy partnerships as concerns that have pressured revenue. CytomX Stock Trading Near Cash Value

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on CTMX shares. Guggenheim lowered their target price on shares of CytomX Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, August 10th. JPMorgan Chase & Co. cut their price target on shares of CytomX Therapeutics from $12.00 to $11.00 and set an "overweight" rating on the stock in a report on Thursday, August 13th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of CytomX Therapeutics in a research note on Tuesday, October 13th. Weiss Ratings reiterated a "sell (d)" rating on shares of CytomX Therapeutics in a report on Friday, September 11th. Finally, Wall Street Zen upgraded shares of CytomX Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.00.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company's approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites.

CytomX's research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.